Volume 8 Supplement 1
Basophil activation test as a biomarker in allergic patients to platins undergoing rapid desensitization
© Giavina-Bianchi et al; licensee BioMed Central Ltd. 2015
Published: 8 April 2015
Rapid Drug Desensitization (RDD) has become a cornerstone of the management of immediate hypersensitivity reactions (HSRs) to chemotherapeutic agents, including biologicals. It is the only effective procedure for overcoming HSRs to first-line therapy, thus representing an important advance in patients’ treatment and prognosis. Biomarkers to assess drug sensitization and monitor RDD safety and efficacy are lacking. Preliminary data suggested that in addition to skin testing, basophil activation test (BAT) could be used to assess patient’s IgE sensitization to platins and provide markers of activation to evaluate the response to RDD.
We studied 12 patients with gastrointestinal and OBGYN cancers who presented hypersensitivity reactions to platins and 6 healthy volunteers who had never been exposed to platins. Skin testing and BAT were done before RDD to platins, and the expression of activation markers CD203c and CD63 was evaluated on basophils (HLADR-/CD41-/CD123+). Most patients were evaluated during 2 or more RDD procedures.
BAT was positive in 9/12 patients (75%), with increased expression of CD203c (9 patients) and CD63 (4 patients). The BAT positivity was 66,7% (6/9) for carboplatin and 100% (3/3) for oxaliplatin. Subsequent BAT analysis in different RDD procedures showed that the test remained positive before each procedure with an even greater expression of CD203c and CD63, indicating temporary tolerance during RDD, which was lost after each exposure. In an attempt to correlate reactions during RDD with specific BAT markers, we observed an association between CD63 expression and the severity of the reactions. All controls had negative tests. Further studies are needed to determine the predictive values of BAT in patients with platins hypersensitivity.
We standardized a BAT to platins with good sensitivity and which can predict patients with severe reactions during RDD. RDD to platinum drugs does not induce persistent hyporresponsiveness on basophils, highlighting the need to maintain repeated RDD in allergic patients to platins.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.